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Background: Nicotine acethylcholine receptors (nAChRs) play critical roles in cognitive 
processes, neuroprotection, and inflammation. Results: According to their 
substituents, 1,3-diphenylpropan-1-one derivatives act as α7 nAChRs negative 
allosteric modulators (OMe) or Type I positive allosteric modulators (PAMs, OH). 
Compounds 7 and 31 were the most effective (989 and 666% enhancement of ACh-
induced currents) and potent (EC50: 12.9 and 6.85 µM) PAMs. They exhibited strong 
radical scavenging values. Compound 31, selective over other neuronal nAChR 
subtypes and with acceptable pharmacokinetic profile, showed antinociceptive effects 
in a model of inflammatory pain. Conclusions: Compound 31 is a novel, potent and 
selective α7 nAChR PAM, displaying antioxidant and analgesic activities. The 1,3-
diphenylpropan-1-one scaffold could be the base toward more advanced PAMs for the 





Alpha7 nAChR  












 Nicotinic acetylcholine receptors (nAChRs) are ligand-gated channels widely expressed 
in the nervous system, and involved in a variety of disorders, including psychiatric, 
neurodegenerative and antiinflammatory processes[1-3]. Among them, the neuronal 
α7 receptor subtype (α7 nAChRs) has attracted considerable interest as a potential 
target for therapeutic intervention in schizophrenia, Alzheimer’s disease and different 
pain conditions [4, 5]. Most of the compounds described as modulators of these 
channels are competitive agonists or antagonists that interact at the orthosteric 
binding site of the endogenous ligand, acetylcholine [2, 6]. However, recent efforts 
have been focused on exploring the pharmacological diversity of compounds able to 
interact with the receptor at allosteric binding sites [7, 8]. These can be allosteric 
agonists, positive allosteric modulators (PAMs), which potentiate the agonist-evoked 
responses without activating or desensitizing the receptor in a direct way, negative 
allosteric modulators (NAMs), able to reduce the effects of the orthosteric ligand, and 
silent allosteric modulators (SAMs) that bind to the allosteric site without producing a 
change in orthosteric binding or efficacy [9]. There are two types of PAMs, differing in 
their effects on receptor desensitization. Type I PAMs have little or no effect on the 
rate of agonist-induced desensitization, while Type II cause a noteworthy duration 
of channel opening, due to delayed desensitization [7]. 
 The search for allosteric modulators of α7 nAChRs is of great interest because 
they could selectively regulate this subtype versus other nicotinic receptors, and even 
homologue serotonine receptors (5-HT3), thus avoiding many of the secondary effects 
associated to ligands that target the highly conserved acetylcholine binding site [8]. 
Despite the limited number of compounds described as α7 nAChR PAMs, several of 
them have advanced towards clinical development [10-23]. Within the families of α7 
nAChR allosteric modulators, a series of cyclopentatetrahydroquinoline-8-sulfonamide 
derivatives is worth mentioning, since they showed different pharmacological 
properties depending on the nature,  number and position of certain substituents [9, 
24].  For instance, minor chemical changes like the configuration, the interchange of 
halogens, or different patterns of methyl substitution in the aromatic moiety at 
position 2 of the tetrahydroisoquinoline ring resulted in either PAMs (Type I or II), 
NAMs, SAMs, or allosteric agonists [9, 24]. 
 Upon screening of a heterogenous collection of small natural products, we  
identified a polyhydroxy substituted chalcone, Isoliquiritigenin (1, Figure 1), as a 
selective Type I PAM of α7 nAChRs [25]. The screening of a collection of one hundred 
commercial chalcones led to the identification of its regioisomer 2, as a potent and 
selective α7 nAChR Type II PAM. This compound was taken as a hit for the preparation 
of a series of polysubstituted chalcone analogues, aimed at improving its 
pharmacodynamic profile. Modifications on the number, position or nature of the 
substituents, led to several analogues with interesting properties as α7 nAChRs PAMs. 
One of the new prepared analogues, compound 3, exhibited much higher potency than 
the model parent compound 2, and a similar increase in the peak of ACh-evoked 
currents mediated by human α7 nAChRs expressed in Xenopus oocytes [25]. In 
addition, compound 3 displayed neuroprotective activities in vitro, and antinociceptive 
effects in a mechanical hyperalgesia in vivo test. Although this compound showed low 
toxicity, the conjugated double bond can be seen as a drug structural alert, because of 
its high chemical reactivity towards oxidation and potential capacity as Michael 
acceptor versus nucleophiles. Therefore, analogues of 3 lacking the α,β–unsaturated 
carbonyl linker could serve to mitigate the risk of potential idiosyncratic drug toxicity 
[26]. 
 To this aim, and to further investigate the potentiality of this series of α7 
nAChRs PAMs, in this contribution we explore the reduction of the double bond or the 
carbonyl group that form the linker chain joining the two aromatic rings in this family 
of chalcones. The transformation of the double bond into a pyrrole ring was also 
performed. While the methoxy-substituted 1,3-diphenylpropa-1-one derivatives 
behave as α7 nAChRs NAMs, the hydroxyl analogues showed, in general, a typical Type 
I PAM profile. One of these derivatives, the reduced analogue of chalcone 2 was shown 
to significantly inhibit thermal hyperalgesia in vivo while the corresponding to chalcone 
3  did not, a different behavior that can be explained in terms of their dissimilar 
pharmacokinetic properties. In addition, the hydroxy 1,3-diphenylpropa-1-ones, as 
well as chalcone 3, show remarkable antioxidant properties. 
 
Results & discussion  
Chemistry 
First, we were interested in the reduction of the double bond of the spacer chain, 
keeping intact the carbonyl group. Starting from methoxy chalcone 4, attempts to 
hydrogenate it over Pd/C were not completely satisfactory, since the main reaction 
product was the alcohol 5, that result from the concomitant hydrogenation of the 
double bond and the carbonyl group, while the desired product 6 was the minor 
component of the reaction. Preparation of 6 was finally achieved in good yield by 
performing the Pd/C hydrogenation in the presence of diphenyl sulfide, a catalyst 
poison that selectively hydrogenates olefin and acetylene functionalities without 
hydrogenolysis of aromatic carbonyls [27]. Polyhydroxylated compound 7 was 
obtained from the methoxy propan-1-one analogue 6 by treatment with BBr3 in Cl2CH2 
[28], the same procedure followed in the preparation of the hydroxychalcone series 
(Figure 2). However, a similar treatment failed in the case of compound 5 that 
decomposed under these reaction conditions. 
 The good α7 nAChR potentiation value found for compound 7, as we will 
comment later, prompted us to prepare the propan-1-one analogues of the rest of our 
previously described hydroxylated chalcones [25]. Thus, hydrogenation of the double 
bond of methoxylated chalcones 8-12 using the Pd-C/Ph2S system led to propan-1-
ones 13-17 in good to excellent yield. Deprotection of the methoxy groups of 13-15 
afforded the expected hydroxy derivatives 18-20, while the treatment of compounds 
16 and 17 with BBr3 in DCM gave untreatable complex mixtures (Figure 3). 
 Alternatively, compounds 24-26, monohydroxylated in ring A, were obtained by 
direct hydrogenation of the corresponding hydroxyl-chalcones 21-23, previously 
prepared by us (Figure 4) [25]. 
 For the synthesis of derivatives monosubstituted in ring B, we first prepared 
monohydroxy dimethoxychalcones 27 and 28, by condensation of commercial 2,5-
dimethoxyacetophenone and the corresponding 2-hydroxy and 4-
hydroxybenzaldehydes. The procedure involved then hydrogenation to propan-1-ones 
29 and 30, and subsequent deprotection of the methoxy groups. Compound 31, the 
reduced analogue of chalcone 2, was obtained in this way, but deprotection of MeO- 
groups of 29 did not work, recovering the starting material unaltered, probably 
because of steric hindrance around the 2’-OMe group.  (Figure 5). 
 On the other hand, attempts to selectively reduce the carbonyl group, keeping 
the double bond unaltered, were unsuccessful. Several assays using BH4Na, alone or in 
the presence of CeCl3, following the methodology described by Luche, [29] led to 
complex mixtures, difficult to handle, due to partial reduction of the double bond and 
formation of unidentified minoritary byproducts that difficulted the purification and 
lowered the yield of the desired compound. 
 The introduction of heterocyclic rings at the linker was also contemplated, 
taking profit of the reactivity of the conjugated double bond. Moreover, the resulting 
products will have a certain analogy with some thiazole and pyrrol derivatives 
described as PAMs of the α7 nicotinic receptor [15, 30]. Several attempts to prepare 
the pyrazol-containing compound by reaction of the chalcone with trimethyl silyl 
diazomethane failed. However, the preparation of pyrrol derivative 32 was achieved 
starting from 3, through the 1,3-dipolar cycloaddition with tosylmethyl isocyanide 
(TOSMIC) in the presence of sodium hydride as base [31]. Further deprotection with 
BBr3 led to the final hydroxy derivative 33 (Figure 6). 
 
Biological evaluation 
 Electrophysiological Studies 
Synthesized compounds were evaluated as modulators of α7 nAChRs expressed in 
Xenopus oocytes. For this purpose, each compound (10 μM) was co-applied with ACh 
(200 μM), and the resulting currents were compared to those induced by ACh alone. 
As shown in Table 1, the precursor derivatives, with methoxy groups, induced in 
general current percentage values below 100% (which is the control value with 200 µM 
ACh alone). Therefore, these compounds act as inhibitors of α7 nAChRs. Maximal 
inhibition was obtained with compounds 6 (15% of current observed with ACh alone), 
16 (26%) and 13 (29%). This behavior was also observed for the related 
tetrasubstituted methoxy-chalcone 4, although the inhibitory capacity was slightly 
lower (35%). Reduced analogues 14 and 15, with three OMe groups in ring A and one 
or two in ring B were poorer inhibitors. Derivatives bearing two OMe groups in ring A, 
and one OH moiety at ring B (29 and 30) were very weak inhibitors . Finally, pyrrole 
derivative 32 showed only marginal inhibitory ability.  
 Experiments to determine if these compounds behave as competitive 
antagonist, competing with ACh for its binding site, or as negative allosteric 
modulators of the α7 channels were performed. 
 Figure 7 features a comparison between compound 6, which is the most potent 
inhibitor, and its chalcone analogue compound 4. When either of the twowas applied 
to oocytes expressing human α7 nAChRs, a substantial decrease was observed in ACh-
evoked ionic currents (Figure 7c & d). Their decay, however, was similar to control 
currents, so that changes in kinetics were not apparent. Concentration-response 
relationships (Figure 7e & f) showed that compound 6 was about 4-fold more potent 
than compound 4 (IC50 for compounds 6 and 4 was 2.1 and 9.1 μM, respectively). ACh 
concentration-response relationships were displaced to the right in the presence of 
compounds 4 and 6 (Figure 7g & h) (EC50 for ACh was 176 μM  in control conditions 
and 2067 μM  and 536 μM in the presence of compounds 4 and 6, respectively). 
Although these data do not rule out a competitive mechanism, that would need a 
Schild analysis, negative allosterism is the most probable mechanism given the 
compounds’ structures and the positive allosteric mechanism of structurally similar 
compounds 7 and 31 (see below).  
 Besides, effects of the hydroxy substituted compounds in α7 nAChR currents 
are shown in Table 2.  In general, all propan-1-one derivatives were less effective in 
potentiating the ACh-evoked currents than the corresponding chalcone analogues. In 
this series, the most efficient α7 nAChR PAMs were 7 and 31, the propan-1-one 
analogues corresponding to the most powerful chalcone derivatives 3 and 2 
respectively. Compounds 7 and 31 at 10 μM were able to enhance the current induced 
by ACh by 989 and 666%, respectively. Therefore, the reduction of the double bond of 
the chalcone linker resulted in about 2-3 fold less efficient PAMs.  
 Figure 8 features main similarities and differences between compounds 31 and 
7. When either of the two was applied to oocytes expressing human α7 nAChRs, a 
clear potentiating effect was observed in ACh-evoked ionic currents (Figure 8c & d), 
although it was less prominent than the one observed for their chalcone analogues 
(compounds 2 and 3, Figure 8c & d).  Unlike compounds 2 and 3, the currents decayed 
relatively fast, so the changes in kinetics were similar to those found for Type I PAMs.  
 Both compounds 31 and 7 showed similar concentration-dependent 
effectiveness (Figure 8e & f) with 15-fold maximal potentiation of currents evoked by 
ACh 200 μM (see Table 3), but 31 was about two-fold less potent than 7, as deduced 
from their potentiating EC50: 12.9 μM and 6.85 μM for 31 and 7, respectively (Figure 8e 
& f and Table 3). These potencies are comparable to those observed in similar 
conditions for other PAMs, such as PNU-120596 (EC50 3.8-5.8 μM) [10, 32], TQS (5.5 
μM) [32], and A-86774 (1.1 μM) [15]. However, maximum efficacy is probably much 
higher in our compounds because enhancements were not only larger than the 4 to 6-
fold maximal potentiation reported in [32], but were also obtained with a higher ACh 
concentration (0.2 vs. 0.1 mM), which would have underestimated the potentiating 
effect. Additionally, comparing the data of Imax and EC50 of propanone 7 with that of 
the parent compound 3, a slight decrease of efficacy and potency was observed, while 
compound 31 displayed lower efficacy but a small increase in potency when compared 
to chalcone 2 (Table 3). 
 The potentiating effect was not much dependent on ACh concentration. As 
shown in Figure 8g & h, when 10 μM of compound 31 or 5 μM of compound 7 
(concentrations close to the corresponding EC50) were co-applied with ACh, the 
resulting ACh concentration-response relationships were shifted to the left, as the ACh 
EC50 values decreased from 176 μM (control) to 38.3 μM and 71.3 μM in the presence 
of 31 and 7, respectively. 
 Compounds 7 and 31 were also evaluated for their activity at α3β4 and α4β2 
nAChRs expressed in Xenopus oocytes, as these two receptor subtypes represent 
typical representatives of peripheral and central heteromeric receptors, respectively. 
While the tetrahydroxy derivative 7 was able to inhibit the currents induced by ACh at 
these heteromeric channels (up to 44%), the trihydroxy analogue 31 did not exert any 
action at these receptors (see SD, Table S1). Therefore, 31 is highly selective towards 
α7 nAChRs. 
 Given the importance of OH groups for our compounds to behave as α7 nAChR 
PAMs, initially we would not have expected activity for the OMe analogues on this 
receptor, but surprisingly they worked as NAMs. Changes of PAMs to other types of 
allosteric modulators have been previously reported for another family of α7 nAChR 
modulators, upon truly very minor chemical modification, like the exchange of 
halogens, S to R configuration change, and modification of the number and/or 
positions of methyl substituents [9, 24]. 
 
 Analgesic Activity 
Agonists and positive allosteric modulators of α7 nAChRs display antinociceptive and 
anti-inflammatory properties in different animal models [7, 18]. For instance, PNU-
120596 induced analgesic activity by its own or combined with choline in the formalin 
pain test, and showed anti-allodynic effects in the CCI neuropathic pain model [33-35]. 
On the other hand, it is reported that different dietary polyphenols, like chlorogenic 
acid (CGA), resveratrol and quercetin derivatives, have antinociceptive effects on 
acute, inflammatory and neuropathic pain models [36-38], although their mechanisms 
of action are not totally understood. 
 We have previously studied PNU-120596 and chalcone 3 (10 mg/Kg) for the 
reduction of thermal and mechanical hyperalgesia resulting from inflammation 
induced by complete Freund’s adjuvant (CFA). Both showed antinociceptive effects in 
the mechanical hyperalgesia test, and lacked significant activity in the thermal assay 
[25].  Main peak of activity was at 2h for PNU-120596 and at 30 min for chalcone 3, 
probably due to different pharmacokinetic drug clearance. 
 When compounds 7 and 31 were tested for their antihyperalgesic properties in 
the above mentioned mechanical test, very different results were obtained. While no 
signs of antinociceptive activity were observed for tetrahydroxy derivative 7 (Figure 9, 
left), the trihydroxy analogue 31 (Figure 9, right) exhibited analgesic activity 
comparable to that demonstrated by PNU-120596 [25]. Compound 31 displayed 
significant activity at 1 h and the maximum peak at 2 h after the injection, like PNU 
derivative. The differences between 7 and 31 in in vivo experiments could be 
accounted for by distinct mechanisms, including the lack of selectivivity of the former, 
the stronger effect on desensitization of the latter, and their different pharmacokinetic 
profiles, as commented in the next section. 
 
 Physicochemical Properties and Preliminary In Vitro ADME (Administration-
Distribution-Metabolism-Excretion) Profile. 
To get an insight on the potential of this series of compounds for further progress in 
the drug development process, we characterized their pharmacokinetic (PK) features. 
Some theoretical and experimental PK parameters of propan-1-one analogues 7 and 
31, showing the best α7 nACh activity, are shown in Table 4, and compared with those 
of the parent chalcone 3. They include physicochemical properties such as molecular 
weight (MW), calculated lipophilicity (CLogP), and polar surface area (PSA). In addition, 
a short in vitro ADME profile for the three compounds was performed, including 
solubility in simulated fluids, ability to bind to plasma proteins, permeability in Caco-2 
cells, and metabolism in human liver microsomes.  
 Taking into account the calculated physicochemical parameters, the low MW 
(<300 Da) and the calculated CLogP (2.51-2.71) and PSA (77-97) values for the three 
compounds were suggestive of probable good oral absorption (Table 4).  
 From the in vitro PK data, compound 3 showed quite limited aqueous solubility, 
especially at pH >7, but propan-1-ones 7 and 31 are more soluble in the three 
simulated fluids. While 3 is a totally planar molecule that could stack to form 
aggregates, the reduction of the double bond necessarily break the planarity, thus 
increasing solubility in 7 and 31. The three compounds bound very strongly to plasma 
proteins (> 95%), but the experimental permeability in Caco-2 cells was clearly 
different among them. The values for compounds 3 and 7 indicated a moderate-to-low 
permeation and a certain probability of efflux. For compound 3, this low permeability 
could be due, at least in part, to the quite limited aqueous solubility in the different 
fluids, but other factors should be responsible for the poor value of 7. Probably, the 
low permeability of compound 7 is the main responsible of its inactivity in the 
analgesia in vivo test. However, the permeability increased by 6- and 10-fold in the 
case of the in vivo active compound 31 with respect to 3 and 7, respectively. The lower 
molecular weight and the PSA value could be behind the higher permeability. In 
relation to microsomal metabolic labilities, all compounds showed acceptable to good 
half-life values for an initial lead compound, but their apparent intrinsic clearances 
were quite high, indicating low hepatic metabolic stability. The 19 min difference in t1/2 
between 3 and 7 indicates that the chalcone double bond is a labile point for metabolic 
modification, probably through oxidation. Similarly, the lower half-life of 31, lacking 
the 2-OH group, when compared to 7 (t1/2  = -24 min) is an indicative of another 
metabolically active position. All these information could help us in designing further 
modifications around the structure of compounds 3, 7 and 31 to improve essential PK 
properties, while maintaining the potency as α7 nAChR PAMs. 
 
 Antioxidant Capacity  
The antioxidant properties of many hydroxy-containing natural products are well 
documented, and it is suspected that this property is behind many of their beneficial 
effects on health, expanding from neuroprotective and antiinflammatory effects to the 
prevention of cancer and cardiovascular diseases [39-42]. Hydroxyl groups of phenols 
are one of the key moieties to enhance antioxidant activity due to its easy conversion 
to phenoxy radicals through a hydrogen transfer mechanism [43]. As our allosteric α7 
nACh modulators bear three or four hydroxy groups on their structures, we decided to 
evaluate their possible antioxidant activity. For this purpose, the oxygen radical 
scavenging capacity of compounds 3, 7 and 31 was measured by the ORAC assay 
(Table 5). All compounds exhibited strong radical scavenging activities, similar or even 
higher than those described for well-known flavonoids [44, 45]. According to these 
results, the antioxidant activity of our compounds is dependent on the number of OH 
groups in the molecule and on the linker joining the phenyl rings. Thus, for 
tetrahydroxy derivatives, the oxygen radical scavenging capacity is higher for the 
reduced compound 7 than for the alkene-counterpart 3. Between reduced 
compounds, the ORAC value is better for the tetra- than for the trihydroxy derivative 
(7 > 31).  
 The combination of antioxidant properties and allosteric potentiation of α7 
nAChRs in a single molecule is a new trend in the therapy of Alzheimer disease (AD). 
This occurs in the case of galantamine [46], a marketed drug for AD treatment, and 
epigallocatechin gallate that acts as a neuroprotecting agent against Aβ toxicity [47]. 





General synthetic and analytical chemistry methods, as well as the characterization of 
new compounds not described in this section are included in the Supporting 
Information. 
 
 Chemistry  
 
 General procedure for the preparation of 1,3-diphenyl-1-propanones: To a 
solution of the corresponding chalcone (0.30 mmol) in MeOH (30 mL) and 
diphenylsulfide (0.003 mmol), Pd/C 10% (10% weight) was added. After 
hydrogenation, at room temperature and 20 psi during 24h, the catalyst was filtered 
off, the solvent evaporated under vacuum, and the residue purified by flash 
chromatography as indicated. 
 
1-(2’,5’-Dimethoxyphenyl)-3-(2,4-dimethoxyphenyl)-1-propanone (6)  
White amorphous solid, 79 mg (78% yield). Eluent: 0 to 25% gradient of EtOAc in 
hexane. HPLC-MS (Sunfire): tR = 10.00 min (10 min gradient: 80 to 95% of A in B). 
1H 
NMR (500 MHz, DMSO), : 2.75 (t, 2H, H), 3.11 (t, 2H, H), 3.72 (s, 6H, OMe), 3.75 (s, 
3H, OMe), 3.79 (s, 3H, OMe), 6.42 (dd, J = 8.2, 2.4 Hz, 1H, 5-H), 6.50 (d, J = 2.4 Hz, 1H, 
3-H), 7.01 (d, J = 8.4 Hz, 1H, 6-H), 7.03 (m, 1H, 4’-H), 7.09 (m, 2H, 3’-H y 6’-H) ppm. 13C 
NMR (125 MHz, DMSO), : 24.1 (C), 43.3 (C), 55.1 (OMe), 55.3 (OMe), 55.5 (OMe), 
56.2 (OMe), 98.3 (C-3), 104.3 (C-5), 113.5 (C-6’), 113.9 (C-3’), 119.0 (C-4’), 121.0 (C-1), 
128.5 (C-1’), 129.8 (C), 129.8 (C-6), 152.2 (C), 157.9 (C), 159.0 (C), 201.1 (CO) ppm. MS 
(ESI+): m/z 331.4 (M+H)+, 353.5 (M+Na)+.  
 
3-(2,4-Dimethoxyphenyl)-1-(3’-methoxyphenyl)-1-propanone (16)  
Prepared following the general method B. Colorless oil, 79 mg (90% yield). Eluent: 0 to 
30% gradient of EtOAc in hexane. HPLC-MS (Sunfire): tR = 8.95 (10 min gradient: 15 to 
95% of A in B). 1H NMR (500 MHz, DMSO), : 2.81 (t, J = 7.6 Hz, 2H, H), 3.20 (t, J = 7.6 
Hz, 2H, H), 3.72 (s, 3H, OMe), 3.76 (s, 3H, OMe), 3.81 (s, 3H, OMe), 6.43 (dd, J = 8.2, 
2.4 Hz, 1H, H-5), 6.52 (d, J = 2.4 Hz, 1H, H-3), 7.07 (d, J = 8.2 Hz, 1H, H-6), 7.20 (ddd, J = 
8.2, 2.7, 0.8 Hz, 1H, H-4’), 7.40-7.46 (m, 2H, H-5’ and H-2’), 7.55 (dd, J =7.8, 1.3 Hz, 1H, 
H-6’) ppm. 13C NMR (125MHz, DMSO), : 24.2 (C), 38.4 (C), 55.1 (OMe), 55.3 (2C, 
OMe), 98.3 (C-3), 104.4 (C-5), 112.3 (C-6’), 119.1 (C-4’), 120.4 (C), 120.9 (C-5’), 129.9 
(C-6, C-2’), 138.0 (C), 157.9 (C), 159.1 (C), 159.4 (C), 199.4 (CO) ppm. MS (ESI+): m/z 
301.4 (M+H)+, 323.4 (M+Na)+.  
 
 General procedure for the deprotection of methoxy substituted compounds: To 
a previously cooled solution (0°C) of the corresponding methoxy substituted 
compound (0.60 mmol) in dried DCM (15 mL), a 1M solution of BBr3 in DCM (2 equiv 
for each MeO- group plus 2 more equiv for every group containing a potentially basic N 
or O) was slowly added under Ar atmosphere. After stirring 24-48 h at room 
temperature under Ar, H2O was added to the reaction mixture. The solid precipitate 
formed was separated by filtration, and washed with H2O and DCM. In the cases when 
no precipitate was observed, the product was extracted with EtOAc. The organic 
extracts were washed with H2O and brine, dried over Na2SO4 and then evaporated. The 
crude product was purified as indicated in each case. 
 
1-(2’,5’-Dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-1-propanone (7) 
Reddish solid, 50 mg (27% yield), mp 150-152ºC. Purification by reverse phase flash 
chromatography. (Eluent: gradient from 2 to 30% of EtOAc in hexane).  HPLC (Sunfire): 
tR = 6.90 min (10 min gradient: 15 to 95% of A in B). 
1H NMR (500 MHz, DMSO) : 2.72 
(t, J = 7.5 Hz, 2H, H), 3.16 (t, J = 7.5 Hz, 2H, H), 6.12 (dd, J = 8.1, 2.4 Hz, 1H, 5-H), 6.27 
(d, J = 2.4 Hz, 1H, 3-H), 6.80 (d, J = 8.8 Hz, 1H, 3’-H), 6.84 (d, J = 8.1 Hz, 1H, 6-H), 6.97 
(dd, J = 8.8, 2.9 Hz, 1H, 4’-H), 7.20 (d, J = 2.9 Hz, 1H, 6’-H), 9.04 (s, 1H, OH), 9.26 (s, 2H, 
OH), 11.34 (s, 1H, OH) ppm. 13C NMR (125 MHz, DMSO) : 24.5 (C), 39.5 (C together 
with the DMSO signal), 102.5 (C-3), 106.0 (C-5), 114.7 (C-6’), 117.4 (C-1), 118.5 (C-3’), 
120.1 (C-1’), 124.3 (C-4’), 130.2 (C-6), 149.5 (C), 153.8 (C), 155.9 (C), 156.6 (C), 205.6 
(CO) ppm. MS (ES+): m/z 275.6 (M+H)+. HRMS (ESI+) m/z calculated for C15H14O5 
(M+H)+ 275.0914, found 275.0917. 
 
1-(2’,5’-dihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone (31) 
Solid, 94 mg (72% yield), mp 105-108°C. HPLC (Sunfire): tR = 7.71 min (10 min gradient: 
15 to 95% of A in B). 1H NMR (500 MHz, DMSO) : 2.80 (t, J = 7.7 Hz, 2H, H), 3.26 (t, J = 
7.7 Hz, 2H, H), 6.66 (d, J = 8.4 Hz, 2H, 3-H and 5-H), 6.80 (d, J = 8.9 Hz, 1H, 3’-H), 6.97 
(dd, J = 8.9, 3.0 Hz, 1H,4’-H), 7.05 (d, J = 8.4 Hz, 2H, 2-H and 6-H), 7.19 (d, J = 3.0 Hz, 1H, 
6’-H), 9.17 (s, 1H, OH), 11.25 (s, 1H, OH) ppm. 13C NMR (125 MHz, DMSO) : 28.8 (C), 
41.0 (C), 114.7 (C-6’), 115.1 (C-3, C-5), 118.4 (C-3’), 120.2 (C-4’), 124.1 (C-1’), 129.2 (C-
2, C-6), 131.0 (C-1), 149.4 (C), 153.5 (C), 155.5 (C), 204.8 (CO) ppm. MS (EI+): m/z 259.2 
(M+H)+. HRMS (ESI+) m/z calculated for C15H14O4  (M+H)
+ 259.09649, found 259.09611. 
 
 Biological procedures 
 
 Oocyte Expression and Electrophysiological Studies.  
All human nAChR cDNAs were cloned in derivatives of the pSP64T vector containing 
part of the pBluescript polylinker. Capped mRNA was synthesized in vitro using SP6 
RNA polymerase, the mMESSAGE-mMACHINE kit from Ambion (Thermo Fisher 
Scientific, Madrid, Spain) and the pSP64T derivatives mentioned above. Defoliculated 
Xenopus laevis oocytes were injected with 5 ng of each subunit cRNA in 50 nL of sterile 
water. All experiments were performed within 2-3 days after cRNA injection. Unless 
otherwise specified, compounds were pre-applied in the bath for 2 min and then co-
applied with ACh through a pipette held very close to the oocyte for fast application. 
Functional expression of each receptor was estimated as the peak ionic current evoked 
by 0.6 s application of 0.2 mM ACh at -80 mV. All experiments were performed at 22°C. 
Current records were measured with Clampfit 10.0 (MDS Analytical Technologies, 
Sunnyvale, CA, USA). Normalized peak currents were obtained by dividing the 
maximum value of the current obtained in the presence of compound by the 
maximum value of the current obtained in control conditions. Dose-response curves 
for the peak current obtained with ACh were fitted to the Hill equation: Normalized 
current = Imax/(1 + (EC50/[ACh])
nH). Data are expressed as mean ± SEM.  
 
 Analgesic assay.  
Male Wistar rats (250-300 g) were obtained from Janvier France. All experiments were 
approved by the Institutional Animal and Ethical Committee of the Universidad Miguel 
Hernandez where experiments were conducted and they were in accordance with the 
guidelines of the Economic European Community and the Committee for Research and 
Ethical Issues of the International Association for the Study of Pain. All parts of the 
study concerning animal care were performed under the control of veterinarians. 
CFA emulsion (1:1 oil/saline, 0.5 mg/mL) was injected into the plantar surface (50 µL) 
of the left hind paw of rats [48]. Compounds were administered at 10 mg/kg i.v. 24 h 
after CFA injection.  
The mechanical allodynia was monitored 24 h after CFA injection and up to 4 h after 
administering the compounds. Paw withdrawal latency to mechanical stimulation was 
assessed with an automated testing device consisting of a steel rod that is pushed 
against the plantar surface of the paw with increasing force until the paw is withdrawn 
(Dynamic Plantar Aesthesiometer; Ugo Basile). The maximum force was set at 50 g to 
prevent tissue damage and the ramp speed was 2.5 g/s. Rats were placed in test cages 
with a metal grid bottom. They were kept in the test cages for 30-40 min to allow 
accommodation. The paw withdrawal latency was obtained as the mean of 3 
consecutive assessments at each time point (at least 10 s between repeated 
measurements of the same paw). 
 
 Oxygen Radical Absorbance Capacity (ORAC) Experiment.  
The ORAC assay was performed following Ou et al. [49], as modified by Davalos et al. 
[44]. All samples and reagents were dissolved in phosphate buffer (75 mM; pH 7.4). 
The reaction was performed in a final volume of 200 μl: 20 μl test samples or 20 μl 
Trolox solutions (0.2 – 2 nM), 120 μl fluorescein solution (1.17 mM) and 60 μl 2,2'-azo-
bis-(2-methylpropionamidine) dihydrochloride (AAPH) 1.3% solution (all from Sigma 
Aldrich) were added to the wells of a black 96-well plate. The fluorescence was 
recorded at 40 °C every 55 s for 95 min using a fluorimeter (SpectraMax M2; Molecular 
Devices, California, USA), with excitation and emission wavelengths of 480 and 520 
nm, respectively. All samples were tested in triplicate. ORAC values were expressed as 
μmol Trolox equivalents/ μmol of pure compound.  
 
Conclusion 
A series of 1,3-diphenylpropan-1-ones have been synthesized and evaluated for their 
activity at α7 nAChRs. Remarkably, the modulation of these nicotinic channels goes in 
opposite directions depending on the phenyl ring substituents. Thus, while OMe-
substituted derivatives inhibited the activation of α7 nAChRs by ACh (probably acting 
as NAMs), most analogues with OH substitutions are type I PAMs. Compounds 7 and 
31 display the best potency and efficacy profiles within the series, and the latter is 
highly selective against α3β4 and α4β2 nAChRs. In in vivo experiments, using an 
inflammatory pain model of mechanical hyperalgesia, compound 31 showed significant 
antinociceptive effects, comparable to that displayed by PNU-120596, while the 
tetrahydroxy analogue 7 was inactive. The about 10-fold lower permeability of 
compound 7, compared to 31, could explain its lack of activity in the in vivo test. In 
addition to the above indicated in vitro and in vivo activities, these compounds 
displayed remarkable antioxidant properties in ORAC experiments. Compounds within 
this 1,3-diphenylpropan-1-one series could serve to restore the impaired sensory 
gating and cognitive deficits in AD, because of their cholinergic connection. Also by 
reason of the fact that oxidative stress and plaque deposition, associated with chronic 
inflammation in the brain, are key events in AD pathogenesis and progression. The 
multiactivity and pharmacokinetic profile of compound 31 could place it as a good 
starting point to improved analogues having potential longer advance in the course of 
the drug development process. Work in this direction is underway in our labs. 
 
Future perspective 
Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an important player of the 
cholinergic nerve system in the brain, associated with the anti-inflammatory pathway 
of the parasympathetic nervous system. Experimental models indicated that vagal 
nerve stimulation attenuates the production of proinflammatory cytokines, inhibiting 
the inflammatory process, probably through the α7 nAChRs. This provides a rationale 
for the utility of α7 nAChR agonists and PAMs in the treatment of inflammatory pain. 
Both central and peripheral α7nAChR has been involved in changes in body weight 
associated to nicotine. As important peripheral mediators of chronic inﬂammation, 
α7nAChRs are also key contributors to obesity. Recent studies identify links between 
α7nAChR expression and obesity, insulin resistance, and diabetes. Therefore, this 
nicotinic channel may also be a useful therapeutic target to treat and manage obesity. 
In addition, the reduction of the α7 nAChR function has been identified as a potential 
mechanism for elevated tobacco consumption and consequently, the activation of α7 
nAChRs could be explored for tobacco cessation therapy. 
The α7- nAChR receptors are expressed by macrophages and its expression is crucial 
for the anti-inflammatory effect of vagal nerve signaling. Nicotine exerts anti-
inflammatory effects on macrophages that can be counteracted by selective α7-
antagonists.[50, 51] Selective α7 nAChR agonists have proven effective in reducing 
macrophage cytokine production and inflammation in animal models of 
pancreatitis,[52] dextran sulfate sodium (DSS)-induced colitis[53] and intestinal 
ileus.[54] Nicotine has been tested in clinical trials as a treatment for inflammatory 
diseases such as ulcerative colitis, but the therapeutic potential of this mechanism is 
limited by the collateral toxicity of nicotine, which support the needed of designing 
new molecules as positive allosteric modulators of α7 nAChR that would have anti-
inflammatory effects while eluding collateral toxicity. 
Finally, α7 nicotinic channels are also implicated in the modulation of different 
cognitive functions such as attention, and working and episodic memory. Increasing 
preclinical and clinical evidences suggest that α7 nAChR activation is of promising 
therapeutic value for the treatment of cognitive impairment associated with 
Alzheimer’s disease (AD) and schizophrenia.  
Nowadays, there are no approved drugs that work through this receptor subtype, 
although several are at different stages of clinical development. Recent promising 
approaches are based on the use of positive allosteric modulators, PAMs, due to their 
several advantages over direct agonists. However, their effects, regarding 
inflammatory pain, nicotine dependence, obesity and cognitive functions during 
neurodegenerative diseases, have not been totally characterized. The present findings 
confirm and extend the observations indicating that the positive allosteric modulation 
of α7-nAChRs displays antinociceptive effects in models of inflammatory pain. The 
antioxidant activity of our compounds could represent an additional advantage for 
studying their potential applications to diseases triggered by multiple mechanisms, like 
obesity and AD. 
All the information that is being generated by preclinical and clinical studies on this 
subject will provide a deeper understanding of the nicotinic pathway in the indicated 
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 The allosteric modulation of α7 nAChRs represents promising therapeutic strategies 
for the treatment of inflammatory pain, and cognitive impairments, among other 
pathological conditions. 
 OMe-substituted 1,3-diphenylpropan-1-ones are able to inhibit the activation of α7 
nAChRs. 
 Hydroxy-substituted 1,3-diphenylpropan-1-one analogues are potent and selective 
α7 nAChR positive allosteric modulators. 
 Compound 31 behaves as a potent and selective α7 nAChR PAM and displays 
antinociceptive activity in an inflammatory pain model. 
 Its antioxidant activity, combined with the properties at the nicotinic pathway, 















Figure 2: Hydrogenation of chalcone 4. Reagents and conditions: (A) H2, Pd on C, 
methanol, r.t., 4h; (B) H2, Pd on C, Ph2S, methanol, r.t., 24h; (C) boron tribromide, 





Figure 3: Preparation of polyhydroxy propan-1-ones. Reagents and conditions: (A) H2, 
Pd on C, Ph2S, methanol, r.t., 24h; (B) boron tribromide, dichloromethane, r.t., Ar 






Figure 4. Synthesis of diphenylpropan-1-ones monohydroxylated in ring A. Reagents 
and conditions: (A) H2, Pd on C, Ph2S, methanol, r.t., 24h. 
 
 
 Figure 5. Preparation of propan-1-ones monohydroxylated in ring B. Reagents and 
conditions: (A) H2, Pd on C, Ph2S, methanol, r.t., 24h; (B) boron tribromide, 
dichloromethane, r.t., Ar atmos, r.t., 24h. 
 
 
Figure 6. Synthesis of pyrrol derivative 33. Reagents and conditions: (A) p-
toluenesulfonylmethyl isocyanide (Tosmic), sodium hydride, diethyl ether, 












































































































































Figure 7. Comparison between compounds 4 (left panels) and 6 (right panels). a-b) 
Chemical structure of the tetrasubstituted methoxy-chalcone 4, and its reduced 
analogue 6. c-d) Ionic currents recorded in representative oocytes expressing human 
α7 nAChRs. Currents were evoked by 600 ms applications of ACh 200 μM in the 
absence (continuous line) and in the presence (dotted line) of 10 μM of 4 or 6. All 
currents were recorded at a holding potential of -80 mV. e-f) Concentration-response 
relationships for the inhibiting effect of 4 and 6 co-applied with ACh 200 μM. 
Continuous lines represent the fit to the Hill equation resulting in IC50 values of 9.1 μM 
and 2.1 μM for 4 and 6, respectively. g-h) Acetylcholine concentration-response 
relationships in the absence (closed circles) and in the presence (open circles) of 10 
M of 4 or 3 μM of 6. These concentrations were chosen because they are close to 
their respective IC50 values. All data were normalized to the response obtained by ACh 















































































































































Figure 8. Comparison between compounds 31 (left panels) and 7 (right panels). a-b) 
Chemical structure of 1,3-diphenylpropan-1-ones 31 and 7. c-d) Ionic currents 
recorded in representative oocytes expressing human α7 nAChRs. Currents were 
evoked by 600 ms applications of ACh 200 μM in the absence (continuous line) and in 
the presence (dotted line) of 10 μM of 31 or 7. For the sake of comparison, 
representative currents obtained with the chalcone analogues 2 and 3 were included. 
All currents were recorded at a holding potential of -80 mV. e-f) Concentration-
response relationships for the potentiating effect of 31 and 7 co-applied with ACh 200 
μM. Continuous lines represent the fit to the Hill equation. Maximal potentiating 
effects were estimated as 15-fold for both compounds, with EC50 values of 12.9 μM 
and 6.85 μM for 31 and 7, respectively. g-h) Acetylcholine concentration-response 
relationships in the absence (closed circles) and in the presence (open circles) of  the 
indicated concentration of each compound. These concentrations were chosen 
because they are close to their respective EC50 values. All data were normalized to the 








Figure 9. Effect of compound 7 and 31 in the CFA-induced paw inflammation model.  
Time course of mechanical hyperalgesia in rats after injection of CFA 0.5 mg/mL (50 µL) 
into the right hind paw with and without administration of compound (10 mg/kg i.v.). 
The diagram shows the paw withdrawal latencies in response to mechanical 
stimulation (n ≥ 6 rats/group). Data are given as mean ± SEM n = 6. 2-Way ANOVA with 
Bonferroni post hoc test. *P <0.05; **P <0.01, ***P <0.001. 
  
Table 1. Structures of methoxy parent compounds and their inhibition % values of α 














































42±3    
a
The substituents 2 to 6 and 2’ to 6’ refer to the positions indicated at the structure shown above. 
Compounds were tested at 10 µM co-applied with 200 µM ACh Responses were recorded at -80 mV and 











 Table 2. Structures of synthetized polyhydroxy synthesized compounds and their 




































133±17    
a
The substituents 2 to 6 and 2’ to 6’ refer to the positions indicated at the structure shown above. 
Compounds were tested at 10 µM co-applied with 200 µM ACh Responses were recorded at -80 mV and 
normalized with respect to that shown by only ACh (200 µM). 
  
Table 3. Imax and EC50 values for the best 
propan-1-ones and comparison with their 
chalcone analogues 
Compound Imaxa EC50 (µM)
a 
2 33.0 ± 9.6 b 25.0 ± 2.8b 
31 15.0 ± 1.9 12.9 ± 1.4 
3 34.0 ± 5.5 3.3 ± 1.6 
7 15.5 ± 1.2 6.9 ± 0.9 
a
Values derived from the corresponding dose 
response curves. Responses were recorded at -80 mV 
and normalized with respect to that shown by only 
ACh (0.2 mM). Data are the mean ± SD, with n ≥ 6. 
b
Extrapolated values, as no response saturation could 
be reached, given the low solubility at higher 
concentrations. 
 
Table 4. Calculated Physicochemical Properties and Short ADME Profile of 
Compounds 3, 7 and 31. 
Property  Compd. 3 Compd. 7 Compd. 31 
MW  272.25 274.27 258.27 
CLogP  2.51a 2.66a 2.74a 
PSA  97.98a 97.9 a 77.75a 
Solubilityb (µM) 
Intestinal fluid 11.6 (LCP) 184.2  188.4  
PBS (pH 7.4) 6.4 (LCP) 176.4 159.9 
Gastric fluid 38.8 (LCP) 185.0 200.4 (ADJ) 
% Protein 
boundc 
 96  97 97 
Permeability 
Caco-2d (cm/s) 
A-B 5.3 x 10-6 3.1x 10-6 33.5 x 10-6 
B-A 19.9 x 10-6 38.5 x 10-6 12.0 x 10-6 
Metabolisme 
Half-life (min) 23 42 18 
CLint (μL/min/mg ) 299.5 165.7 387.1 
a
Calculated using Molinspiration (http://www.molinspiration.com).  
b,c,d,e
Performed by CEREP. LCP = low chromatography purity due to compound instability (trans-cis 
isomerism) at room temperature in PBS solution. ADJ = Solubility greater than 200 µM, adjusted to the 
maximum assay concentration (200 µM). 
 
  
 Table 5. Results of the ORAC assay 
Compd. 
µM TE/µmol of pure 
compound 
3 4.5 ± 0.6 
7 7.0 ± 1.8 
31 2.7 ± 0.1 
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